

Contents

| | |
|---|----|
| Molecular Modeling of Neurotransmitter Receptors S.G. DAHL, Ø. EDVARDSEN, and I. SYLTE. With 2 Figures | 1 |
| Structure–Function Analysis of the Three β-Adrenergic Catecholamine Receptors A.D. STROSBURG. With 2 Figures | 9 |
| Serotonin Receptor Subtypes P.R. HARTIG, N. ADHAM, J. ZGOMBICK, M. MACCHI, H.-T. KAO, L. SCHECHTER, T. BRANCHEK, and R. WEINSHANK. With 1 Figure and 4 Tables | 15 |
| Developmental Regulation of 5-HT₂ and 5-HT_{1c} Receptor Gene Expression in Rat Brain R.D. CIARANELLO, J. AIMI, R. DEAN, R. DESAI, S. GARLOW, M.R. HELLER, D. MORILAK, and B.L. ROTH. With 2 Figures | 26 |
| Relevance of 5-HT Autoreceptors for Psychotropic Drug Action M. GÖTHERT and E. SCHLICHER. With 2 Figures and 2 Tables | 38 |
| Brain Serotonin Subsystem Complexity and Receptor Heterogeneity: Therapeutic Potential of Selective Serotonin Agonists and Antagonists K.P. LESCH, C.S. AULAKH, and D.L. MURPHY. With 1 Figure and 3 Tables | 52 |
| Serotonin Receptors and Antipsychotic Drug Action H.Y. MELTZER. With 2 Tables | 70 |
| The Third Dopamine Receptor (D₃): New Perspectives in Therapeutics B. GIROS, P. SOKOLOFF, M.P. MARTRES, L. LANNFELT, M. ANDRIEUX, R. BESANÇON, C. PILON, M.L. BOUTHENET, E. SOUIL, and J.C. SCHWARTZ. With 4 Figures and 1 Table | 82 |

| | |
|--|------------|
| PET Examination of Central D₂ Dopamine Receptor Occupancy in Relation to Extrapyramidal Syndromes in Patients Being Treated with Neuroleptic Drugs | |
| L. FARDE and A.-L. NORDSTRÖM. With 1 Figure and 1 Table | 94 |
| Dopaminergic and Serotonergic Aspects of Acute Extrapyramidal Syndromes | |
| D.E. CASEY. With 1 Table | 101 |
| Methods to Facilitate Early Exploratory Testing of Novel Psychopharmacologic Agents in Humans | |
| W.Z. POTTER and R.P. IRWIN. With 1 Figure and 2 Tables | 111 |
| Neuroleptics and Diagnostic Heterogeneity in Relation to Drug Evaluation | |
| F.-A. WIESEL | 124 |
| Residual and Negative Symptoms in Treatment with Neuroleptics | |
| J.M. KANE | 131 |
| Clinical Dosing of Neuroleptics | |
| R.J. BALDESSARINI, B.M. COHEN, and M.H. TEICHER. With 3 Tables | 138 |
| Diagnostic Heterogeneity in Relation to Drug Evaluation: Antidepressants | |
| E.S. PAYKEL. With 2 Tables | 149 |
| Dose-Effect Relationships for Tricyclic Antidepressants: The Basis for Rational Clinical Testing of New Antidepressants | |
| L.F. GRAM. With 2 Figures and 3 Tables | 163 |
| Dose-Effect and Concentration-Effect Relationships with New Antidepressants | |
| S.H. PRESKORN. With 1 Figure and 8 Tables | 174 |
| Therapeutic Potentials of Recently Introduced Antidepressants | |
| P. VESTERGAARD, L.F. GRAM, P. KRAGH-SØRENSEN, P. BECH, N. REISBY, T.G. BOLWIG, and the DANISH UNIVERSITY ANTIDEPRESSANT GROUP. With 6 Tables | 190 |
| Role of Genetic Polymorphism in Psychopharmacology - An Update | |
| K. BRØSEN, S.H. SINDRUP, E. SKJELBO, K.K. NIELSEN, P. NØRREMARK, and L.F. GRAM. With 2 Figures and 3 Tables | 199 |
| Psychotropic Drug Metabolism and Clinical Monitoring | |
| A.E. BALANT-GORGIA and L.P. BALANT | 212 |

| | |
|---|-----|
| Disposition of the Neuroleptics Perphenazine, Zuclopenthixol, and Haloperidol Cosegregates with Polymorphic Debrisoquine Hydroxylation L. BERTILSSON, M.L. DAHL, B. EKQVIST, and A. LLERENA. With 5 Figures and 1 Table | 230 |
| Phenotypes for Psychotropic Drug Metabolism in the Elderly B.G. POLLOCK and J.M. PEREL. With 3 Figures | 238 |
| Analysis of 935 Haloperidol Concentration Measurements Obtained During Routine Drug Monitoring of 134 Patients M. GEX-FABRY, A.E. BALANT-GORGIA, and L.P. BALANT. With 4 Tables | 246 |
| Power Analysis for Correlation of Plasma Level and Clinical Data J.M. DAVIS and Z. WANG. With 5 Tables | 253 |
| Subject Index | 265 |